Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
Launched by NORTHWELL HEALTH · Oct 31, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to detect and monitor gynecologic cancers, particularly those related to the human papilloma virus (HPV), which affects many women each year. Currently, diagnosing these conditions often requires invasive tests, but researchers are exploring a simple blood test that could identify specific DNA from cancer cells in the blood. This test, developed by a company called Naveris, aims to tell the difference between early-stage (pre-cancerous) and more advanced (invasive) cervical cancers.
To participate in the trial, women aged 18 and older who have been diagnosed with high-grade cervical dysplasia or invasive cervical cancer are eligible. During the study, participants will provide blood samples, which will be analyzed to see if the new test can effectively detect the presence of cancer-related DNA. This research could lead to less invasive and more accessible screening options for women with HPV-related cancers, making it easier to monitor and manage their health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • All patients above age 18, with biopsy proven HPV-related high-grade cervical dysplasia or invasive cervical cancer will be included.
- Exclusion Criteria:
- • Persons who do not meet the above inclusion criteria.
About Northwell Health
Northwell Health is a leading integrated health system based in New York, dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to improving patient outcomes and enhancing medical knowledge, Northwell Health conducts a diverse range of clinical studies across various therapeutic areas. The organization harnesses its extensive network of hospitals, outpatient facilities, and research institutes to facilitate cutting-edge research, ensuring access to advanced treatments for patients while fostering collaboration among healthcare professionals, researchers, and industry partners. By prioritizing patient-centric approaches and leveraging state-of-the-art technology, Northwell Health aims to drive significant advancements in medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials